Document Detail


Microvascular reactivity in lean, overweight, and obese hypertensive adolescents.
MedLine Citation:
PMID:  20552222     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSION: The endothelium-dependent microvascular reactivity was not significantly attenuated in the hypertensive adolescents in contrast with the impaired endothelium-independent vasorelaxation in the lean and obese hypertensives.
Authors:
Péter Monostori; Akos Baráth; Ildikó Fazekas; Eszter Hódi; Adrienn Máté; Ildikó Farkas; Zsuzsanna Hracskó; Ilona S Varga; Viktória Sümegi; Balázs Gellén; Csaba Bereczki; Sándor Túri
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-06-16
Journal Detail:
Title:  European journal of pediatrics     Volume:  169     ISSN:  1432-1076     ISO Abbreviation:  Eur. J. Pediatr.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-09-22     Completed Date:  2011-02-23     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  7603873     Medline TA:  Eur J Pediatr     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1369-74     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Blood Pressure
Child
Female
Follow-Up Studies
Humans
Hypertension / blood,  complications*,  physiopathology
Laser-Doppler Flowmetry
Male
Malondialdehyde / blood
Microcirculation / physiology*
Obesity / blood,  complications,  physiopathology*
Overweight / blood,  complications,  physiopathology*
Oxidative Stress
Prognosis
Risk Factors
Thinness / blood,  complications,  physiopathology*
Vasodilation / physiology
Young Adult
Chemical
Reg. No./Substance:
4Y8F71G49Q/Malondialdehyde

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Atrial arrhythmogenicity in aged Scn5a+/DeltaKPQ mice modeling long QT type 3 syndrome and its relat...
Next Document:  The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon ...